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Abstract
Monomeric α-synuclein (αSN) species are abundant in nerve terminals where they are hy-
pothesized to play a physiological role related to synaptic vesicle turn-over. In Parkinson’s
disease (PD) and dementia with Lewy body (DLB), αSN accumulates as aggregated solu-
ble oligomers in terminals, axons and the somatodendritic compartment and insoluble fila-
ments in Lewy inclusions and Lewy neurites. The autosomal dominant heritability
associated to mutations in the αSN gene suggest a gain of function associated to aggregat-
ed αSN. We have conducted a proteomic screen to identify the αSN interactome in brain
synaptosomes. Porcine brain synaptosomes were fractionated, solubilized in non-
denaturing detergent and subjected to co-immunoprecipitation using purified recombinant
human αSNmonomers or oligomers as bait. The isolated αSN binding proteins were identi-
fied with LC-LTQ-orbitrap tandem mass spectrometry and quantified by peak area using
Windows client application, Skyline Targeted Proteomic Environment. Data are available
via ProteomeXchange with identifier PXD001462. To quantify the preferential binding an
average fold increase was calculated by comparing binding to monomer and oligomer. We
identified 10 proteins preferentially binding monomer, and 76 binding preferentially to
oligomer and a group of 92 proteins not displaying any preferred conformation of αSN. The
proteomic data were validated by immunoprecipitation in both human and porcine brain
extracts using antibodies against monomer αSN interactors: Abl interactor 1, and myelin
proteolipid protein, and oligomer interactors: glutamate decarboxylase 2, synapsin 1, glial
fibrillary acidic protein, and VAMP-2. We demonstrate the existence of αSN conformation
selective ligands and present lists of proteins, whose identity and functions will be useful for
modeling normal and pathological αSN dependent processes.
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Introduction
The neurodegenerative a-synucleinopathies are dominated by PD, DLB, and multiple system at-
rophy (MSA), which are characterized by aggregation and deposition of aSN [1, 2]. aSN is a 14
kDa natively unfolded protein, and in vitro studies have shown that monomeric, soluble oligomer-
ic, and insoluble fibrillar species of aSN exists in equilibrium [3–5]. aSN is normally located in the
presynaptic nerveterminals in high concentrations [6]. The function of aSN in the nerve terminal
remains ambiguous, but recent reports suggest a functional role as chaperone for the SNARE com-
plex [7]. aSN is causally linked to autosomal dominant forms of PD where missense mutations in
aSN (A30P, E46K, A53T, H50Q, and G51D) [8–12] and multiplications of the normal aSN cod-
ing reading frame cause autosomal dominant PD and DLB [13, 14]. Moreover, GWAS studies
have identified variation in the aSN gene as the strongest genetic risk factor for sporadic PD
[15–17], and substitutions of A18T and A29S have been associated with sporadic PD [18].
The autosomal dominant disease associated mutations of aSN suggest a gain of toxic func-
tion and the soluble aSN oligomers are hypothesized to represent the culprit (Reviewed in
[19, 20]) based on biophysical, cellular and in vivo studies in models and man [21–24]. Evi-
dence suggests aSN aggregation begins in nerve terminals and spread from synapses via axons
to cell bodies forming Lewy neurites and Lewy bodies [25]. Hence, presynaptic proteins that
interact with aggreated aSN species may represent the first neuronal partners in protein net-
works that are off-set by early aSN aggregates and recent data on prion-like spreading of aSN
pathology in mouse suggest a role for transsynaptic spreading of aSN pathology [26, 27].
Mass spectrometry based proteomic analyses are powerful tools to profile changes in pro-
teins and identify protein-protein interactions in biological systems [28, 29]. aSN has previous-
ly been the target for studies of its presence and post translational modifications [30–32]. aSN
binding partners have been investigated in co-immunoprecipitation experiments in cell ex-
tracts, e.g. subjected to oxidative stress [33, 34] and in brain extracts for Ser-129 phosphoryla-
tion dependent interactions and targets for insoluble aSN filaments [35, 36].
To investigate the interactome disease-related oligomeric aSN in a preparation as close to
its normal subcellular localization we used purified porcine brain synaptosomes. We conducted
semi-quantitative comparison of the interactions for monomeric and oligomeric aSN to get an
impression on the potential gain-of-function caused by the process of aggregation. The aSN
oligomers used in this screen share structural similarities with oligomer species present in
human dementia with Lewy body brain tissue and species developing in aSN transgenic mouse
at the time of degeneration [21, 22]. Synaptosomes have classically been used as the starting
material for purifying synaptic vesicles because they are enriched in axonal nerve terminals,
but also contains mitochondria, myelin and other brain cell structures [37]. Because sample
complexity and the wide dynamic range of concentrations of analytes counteracts the ability of
our MS based strategy to characterize the potential aSN interactome proteome, we reduced
sample complexity by subfractionating the crude synaptosomal preparation into synaptosomal
membranes, synaptosomal lysate, synaptic vesicles, and cytosol prior to non-denaturing deter-
gent extraction [38]. The extract was incubated with purified aSN monomers or oligomers
prior to co-immunoprecipitation (Co-IP) using anti-aSN antibodies. The interacting proteins
were identified by label-free proteomic analysis on a LC-LTQ-orbitrap tandem mass spectrom-
eter followed by a semi-quantitative analysis using Skyline Targeted Proteomic Environment
[39]. Based on the quantitative analysis, we could group the ligands in three classes of interact-
ing proteins, preferential monomeric (MP), preferential oligomeric (OP), and aSN interacting
proteins with no detectable conformational preferences (NPB). Among the ligands were pro-
teins involved in pathways genetically associated to PD and functionally linked to aSN depen-
dent degeneration, e.g. VAMP-2. The identification of aSN targets and their semiquantitative
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binding preference for monomeric versus oligomeric aSN bring information that can substan-
tiate current and and help build future hypotheses and models.
Materials and Methods
Production and isolation of αSNmonomer and oligomer
Human recombinant aSN was produced as described previously [40]. In order to prepare
monomer and oligomer, lyophilized aSN was dissolved in PBS (7.2 mM Na2HPO4, 2.8 mM
NaH2PO4, 140 mMNaCl, pH 7.4) to a final concentration of 10 mg/ml (690mM) and incubated
for 30 min on ice. The dissolved protein was centrifuged on a tabletop centrifuge at 14,800 rpm
for 5 min at 4°C and afterwards loaded on a Superdex 200 10/30 GL column (GE Healthcare)
and eluted with 0.5 ml/min PBS [41]. Oligomers were collected from 17–22 min, and monomer
aSN was collected at 35 min (Fig. 1) Protein concentrations of the fractions were determined
by Bicinchoninic acid protein concentration assay (BCA) (Pierce).
Preparation of synaptosomal lysates from porcine brain
The synaptosomal fractions were prepared as described previously [42], with minor modifica-
tions. A schematic flowchart of the preparation of the synaptosomal fractions can be found in
S1 Fig. After collecting fresh porcine brain tissues (Jensen’s Slagtehus, DK), all steps were car-
ried out on ice or at 4°C. The cortical grey matter region was dissected to avoid myelin-rich
areas. The harvested tissue was homogenized in 3 x volume (w/v) ice-cold homogenization
buffer (320 mM sucrose, 4 mMHEPES–NaOH, 2 mM EDTA, and Complete protease inhibitor
mix (Roche), pH 7.4) using a loose-fitting glass-Teflon homogenizer (10 up-and-down strokes,
700 rpm). The homogenate was centrifuged for 10 min at 1000 G in a Sorvall RC 5C plus cen-
trifuge. The resulting pellet (P1) was discarded, while the supernatant (S1) was collected and
centrifuged for 15 min at 12 000 G. The supernatant (S2) was removed, and the pellet (P2) was
washed by resuspension in 30 mL of homogenization buffer and recentrifuged for 15 min at 13
000 G to yield a supernatant, S20, and a pellet, P20. The latter pellet represents a crude synapto-
somal fraction, which was subsequently resuspended in homogenization buffer, then homoge-
nized in a glass-Teflon homogenizer. 10 x (v/v) ice-cold water containing protease inhibitors
were added, and the whole suspension was immediately subjected to five up-and-down strokes
at 1000 rpm. (hypotonic lysis). 1 M HEPES–NaOH buffer (pH 7.4) was immediately added to
a final concentration of 10 mMHEPES followed by 30 min incubation on ice. The lysate was
centrifuged for 20 min at 33 000 G to yield the lysate pellet (LP1—synaptosomal membranes)
and a lysate supernatant (LS1—synaptosomal lysate). Subsequently, the supernatant was cen-
trifuged for 2 hours at 260 000 G in Beckman Optima LE-80K ultracentrifuge. The supernatant
was isolated (LS2—high speed cytosol) and pellet (LP2—synaptic vesicles) was resuspended in
homogenization buffer. Complete protease inhibitor (Roche) and Triton X-100 to a final con-
centration of 0.5% were added to all samples.
Preparation of synaptosomal lysates from human brain
The human brain tissue from an 80 year old neurological intact male patient was from the
South Australian Brain bank. The synaptosomal fractions were prepared as described for the
porcine brain.
Co-immunoprecipitation of αSN binding proteins
2 mg purified aSN monomer or aSN oligomer was incubated with 1 mg/ml synaptosomal ly-
sate, synaptosomal membranes, synaptic cytosol, or synaptic vesicles in PBS, 0.5% Triton
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X-100 in a total volume of 1 ml at 4°C in rotating tubes overnight. Affinity purified rabbit poly-
clonal aSN specific antibody (ASY-1) covalently bound to Sepharose beads 4B (GE Healthcare)
was added in a 5 times molar excess (5 IgG: 1 aSN) to the samples followed by 2 hours incuba-
tion at 4°C in rotating tubes. The Sepharose beads were isolated and washed twice with PBS,
0.5% Triton X-100, and Co-IP proteins were eluted by incubation in non-reducing SDS loading
buffer for 2 hours at room temperature. Three individual Co-IP were conducted in the four
Figure 1. Isolation and characterization of αSNmonomers, oligomers, and synaptosomal fractions for co-immunoprecipitation experiments. (A)
αSN oligomers formed by reconstitution of lyophilized monomeric recombinant human αSNwas isolated by gelfiltration. Oligomers (O) were collected from
17–22 min, and monomer αSN was collected at 35 min. The dashed line shows chromatogram of globular protein standards, ferritin (450 kDa), catalase (240
kDa), albumin (68 kDa), and ovalbumin (45 kDa). (B) The misfolded state of the oligomers was demonstrated by dot blotting of 250 ng αSNmonomer and
oligomer in duplicates using the aggregate-specific antibody Fila-1 and the total loading of αSN on the filter by pan α-synuclein antibody (αSN BD).
(C) Characterization of the porcine synaptosomal fractions used for pull-down experiments. 30µg from synaptosomal membranes (LP1), synaptosomal
lysate (LS1), synaptic vesicles (LP2) and synaptosomal cytosol (LS2) were immunoblottet and presence of specific markers for synaptic vesicle
synaptophysin, endoplasmic reticulum 78 kDa glucose-regulated protein (GRP78), mitochondria voltage-dependent anionic channel (VDAC), lysosomal
LAMP-2a, and α-tubulin. (D) The stability of the isolated αSNmonomer and oligomer in brain fractions during the co-immunoprecipitation protocol was
studied by a subsequent gel filtration. Detergent extracts of porcine brain (LS2) was incubated with buffer as negative control (Lysate), monomer (Lysate + M)
and oligomer (Lysate + O) for 24 h at 4oC, followed by gelfiltration. Samples from fractions eluting corresponding to O, M and a fraction eluting at 25 min
between monomer and oligomer were resolved by SDS-PAGE and subjected to immunoblotting with monoclonal anti-α-synuclein antibody (αSN BD). The
nature of αSN does not change either as demonstrated by the blot of recombinant monomeric αSN. Clearly the monomer migrates in the M fraction and the
oligomer predominantly in the O fraction. The level of endogenous porcine αSN is low compared to exogenous recombinant αSN.
doi:10.1371/journal.pone.0116473.g001
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described synaptosomal preparations using either monomeric, oligomeric aSN, or buffer as
negative control, resulting in 36 samples to be analyzed by mass spectrometry.
Mass spectrometric peptide mapping
Samples were tryptic digested, and analyzed by LC-LTQ-Orbitrap mass spectrometry as previ-
ously described [43] but with minor modifications. Briefly, digested samples were acidified
with 0.1 volume of 10% formic acid and cleaned using Ultra Microspin columns (Cat# SUM
SS18V, The Nest Group, Southborough, MA, USA) following manufacturer’s instructions.
Samples were then dried to completion in a rotor speed vacuum and resuspended in 80 ml of
98% ddH2O, 2% acetonitrile, 0.1% formic acid for analysis. Liquid chromatography was
performed using a Waters NanoAcquity UPLC (Waters Corporation, Milford, MA). Peptides
were separated online with 75 mm i.d. × 20 cm home-packed fused silica columns (100 Å
Magic C18AQ: Michrom Bioresources, Auburn, CA, USA) with a 125 min 5–90% acetonitrile/
water gradient containing 0.1% formic acid. All data were acquired on a LTQ-Orbitrap XL
mass spectrometer (Thermo Corporation, San Jose, CA). Data Dependent Acquisition mode
was employed for this instrument using a “Top 10”method and 125-minute acquisition time.
The high resolution (mass accuracy: 5 ppm or less) MS data was acquired (60,000 at 400m/z)
followed by 10 ion trap MS/MS acquisitions. The AGC target value for the precursor scan was
1E6 counts and for the ion trap MS/MS scans to 3E4 counts at a minimumMS signal level of
2000 counts and an isolation window of 1.6m/z. Charge state screening was considered for all
MS/MS targets, utilizing only +2,+3, and +4 charge state isotope distribution. Dynamic exclu-
sion was used with parameters set at 1 repeat count, 30 second repeat duration, 500 item exclu-
sion list size, and an exclusion duration of 180 seconds. The mass spectrometry proteomics
data have been deposited at the PRIDE partner repository (dataset identifier PXD001462) of
the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) [44].
Semi-quantitative identification of proteins based on mass spectrometric
peptide mapping
RAW data files were converted to mgf and mzXML files using MS Convert (Proteowizard,
v3.0.3951). The mgf were then searched using ProteinPilot v4.1 (AB SCIEX, Framingham, MA,
USA) referencing a Sus Scrofa database containing all canonical sequences plus all manually
reviewed isoform sequences retrieved from UniProt (July 2012; 26,685 protein entries) for pep-
tide and protein identification. Default settings for peptide assignments and protein identifica-
tions were used (e.g., Identification as the Sample Type, Biological modifications as the ID
Focus, and Unused ProtScore of 0.05 as the Detected Protein Threshold). In case that multiple
proteins are identified by the software as equivalent “winners” (i.e., they share all or nearly all
of the same peptides identified in the sample and are usually different isoforms in a protein
family), the first one is arbitrarily chosen as the representative winner presented in the tables.
The mzXML files were searched using X Tandem! Database searching as part of the TransPro-
teomics Pipeline (Institute for Systems Biology) to create spectral libraries; static carbamido-
methyl modifications to cysteine and variable oxidation of methionine, as well as allowance for
two missed tryptic cleavages were considered. The resulting ~pep.xml result files were grouped
according to experimental condition in Skyline (v 1.3, MacCoss Lab, Department of Genome
Sciences, University of Washington, Seattle, WA, USA) to create distinct spectral libraries. 36
spectral libraries were generated from the three biological replicates of Co-IP from the four
different synaptosomal preparations (LP1, LS1, LP2, LS2) using the three different baits (PBS,
monomer, and oligomer). All peptides from these libraries were added to the project to popu-
late the peptide list, resulting in 11087 peptides derived from 2049 Sus scrofa proteins. The 36
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RAW files from the experimental isolation conditions were then imported to create the MS1
Extracted Ion Chromatograms (XIC) for each peptide. From the spectral libraries, the identifi-
cation retention time was indicated on these XICs where identification was made from the
database search for that RAW file. This was done in Skyline by making connections between
the RAW filename and the pep.xml filename in the spectral library. All peptide XICs were
manually inspected and only peptides that had at least two positive identifications were re-
tained. Additionally, peak assignments were manually corrected for all files based on these
identification retention times, ensuring the correct MS1 signal was integrated. To further vali-
date the specificity of these peak assignments, XICs were created in Skyline for all precursor
isotopes, a predicted isotopic distribution of the peptide sequence was then calculated, and this
predicted ratio was compared with the actual isotopic ratios for the MS1 signal of all peaks.
From this, an ‘idotp’ dot product number, where 1.00 is a perfect match, was generated in Sky-
line. These idotp values were also considered for peak assignment. Identified proteins were
pre-filtered by excluding proteins with higher peak areas in buffer controls than both monomer
and oligomer samples. Peak areas of the remaining proteins were logarithmic transformed in
order to reduce the variability between the biological replicates and normalized to averaged
peak areas of buffer-control. The average fold increase was calculated as the ratio between peak
areas for monomer and oligomers for monomer preferential binding proteins and as ratio
between peak areas for oligomers and monomers for preferential oligomer binding proteins. In
order for a protein to be considered as either monomer or oligomer binding Student’s t-test
was applied and conventional significance of 95% was accepted. The criteria of 2-fold in-
crease in average fold increase has to be fulfilled in order to be considered as preferential bind-
ing protein, similar to the criteria set up in the phospho-peptide interaction study by
McFarland et al. [35]. Based on the filtering aSN preferential monomer binding proteins are
listed in Table 1, and preferential aSN binding proteins are listed in Table 2. Proteins with sig-
nificant higher binding to aSN compared to buffer are listed as non-conformation specific aSN
binding proteins in Table 3. The porcine proteome is not completely described and unknown
proteins are listed with the predicted name derived from an Ensembl automatic analysis pipe-
line. A flowchart of how quantitative data was obtained from sample preparation to semi-
quantitative analysis including criteria for exclusions/inclusion is presented in S2 Fig., and
semi-quantitative data can be found in S1 Table along with number of identified peptides,
number of quantified peptides, and percent sequence coverage.
Validation of protein targets by immunoblotting
Antibodies targeting the proteins selected for validation were tested by immunoblotting on all
four subcellular fractions and the fraction with the highest signal was used as source for the vali-
dating co-IP (S3 Fig.). Proteins were resolved on 10–16% gradient SDS-PAGE under reducing
conditions followed by immunoblotting, as described previously [45]. Quantification of band in-
tensity on western blot was conducted in Image J (Research Services Branch, http://rsb.info.nih.
gov/ij/index.hmtl). For the anti-aSN immunoblot in Fig. 1C-D, the filter was fixed in 0.4% PFA
for 30 min at room temperature to reduce dissociation from the PVDFmembrane, and boiled in
PBS for 5 min prior to blocking followed by conventional immunoblotting procedure [46].
Antibodies
Poly-clonal rabbit anti-aSN, ASY-1 and the aSN aggregation-specific Fila-1 were produced in
house [22, 45, 47, 48]. Rabbit polyclonal anti-GFAP (Z0334) was purchased from Dako. Rabbit
polyclonal anti-Glutamate decarboxylase 2 (ab49832), rabbit polyclonal anti-Synapsin I
(ab64581), rabbit polyclonal anti-synaptophysin (ab8049), rabbit polyclonal anti-a-VDAC1
Identification of Synaptosomal Proteins Binding to α-Synuclein
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(ab15895), and anti-LAMP2a (ab18528) were purchased from Abcam. Mouse monoclonal
anti-Abl Interactor 1 (MABS273) was purchased fromMilipore. Mouse monoclonal anti-mye-
lin proteolipid protein (ST-MCA839G) was purchased from AbD Serotec/BIO RAD. Mouse
monoclonal anti-BiP/GRP78 (610979) and mouse monoclonal anti-aSN (BD, 610787) were
purchased from BD Transduction Laboratories™. The rabbit polyclonal anti-VAMP-2 antibody
was produced as previously described [49].
Results
aSN oligomers can be formed in vitroin various ways e.g. oxidatively modified by dopamine
[50]. We isolate spontaneously assembled, non-covalently modified aSN oligomers by gel fil-
tration [41], which display the FILA-1 epitope that is shared with oligomers present in human
dementia with Lewy body brain tissue and aSN transgenic mouse [21–23]. Such oligomers are
structured but readily depolymerized upon denaturation [51]. Fig. 1A demonstrates the oligo-
mers elute between 17 and 22 min and this pooled fraction is designated O. The monomers
elute between 32 min and 37 min and the fraction collected at 35 min, designated M, was used
for the further investigations. The presence of aggregate specific epitopes on oligomers, but not
monomers, are demonstrated by their binding of the antibody Fila-1 (Fig. 1B), which bind an
epitope that is shared with mature fibrils and occur in pathological aSN aggregates in brain
[21–23].
aSN is predominantly a presynaptic protein so we investigated fractions of brain synapto-
somes rather than crude brain homogenates in search for potential binding partners for exoge-
nous monomeric and oligomeric aSN. The non-denaturing detergent Triton X-100 (0.5%) was
Table 1. Preferential αSN monomer interacting proteins.
Protein UniProt/ swiss-Prot Synapto-somal fraction Fold increase p-value
Mitochondria
Cytochrome b-c1 complex subunit 2 F1RPD2_PIG LP2 16 <0.03
Stomatin protein 2 F1SIH5_PIG LP1 5 0.02
GABA aminotransferase(4-aminobutyrate aminotransferase) GABT_PIG LP1 23 <0.01
Fumarylacetoacetate hydrolase domain-containing protein 2 F1SU52_PIG LP1 6 <0.01
Plasma membrane
Myelin proteolipid protein*; MYPR_PIG LS1 3 0.03
Cytoplasm
Abl interactor 1* F1RTW7_PIG LP2 2 <0.01
Phosphatidylethanolamine-binding protein 1 F1RKG8_PIG LP1 16 <0.01
TNF receptor-associated protein 1 F1RK45_PIG LP1 6 0.02
Tropomodulin-2 F1RZB5_PIG LP2 8 0.01
Vesicle
V-type proton ATPase subunit F F1SMN6_PIG LP1 9 <0.01
Co-immunoprecipitations of proteins from detergent extracts of porcine synaptosomal fractions using recombinant αSN monomer, αSN oligomer, or buffer
as bait, were conducted, and the interacting proteins were identiﬁed by LC-LTQ orbitrap tandem mass spectrometry. The identiﬁed proteins are speciﬁed
by name, Uniprot/swiss-Prot entry, and the synaptosomal fraction in which they were identiﬁed. Quantitative analyses were based on Peak Area Intensity
of peptides occurring in at least two of three individual immunoprecipitations. The average fold increase is calculated as the ratio between the peak areas
for monomer and oligomers for monomer preferential binding proteins. The criteria of  2 fold increase compared to oligomer had to be fulﬁlled in order to
be considered a preferential αSN monomer binding protein. In order for a protein to be considered as either monomer or oligomer binding Student’s t-test
was applied to the logarithmic transformed peak areas and signiﬁcance < 0.05 was accepted.
* indicates the monomer preferential proteins that were validated by western blotting in Fig. 3.
doi:10.1371/journal.pone.0116473.t001
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Table 2. αSN oligomer interacting proteins.
Protein UniProt/
swiss-Prot
Synapto-
somal
fraction
Fold
increase
p-
value
Protein UniProt/
swiss-Prot
Synapto-
somal
fraction
Fold
increase
p-value
Mitochondrial
3-hydroxyacyl-CoA
dehydrogenase type-2
F1RUI1_PIG LP1 6 0.01 2-oxoglutarate/
malate carrier
protein
F1RFX9_PIG LP2 4 0.05
ADP/ATP translocase 3 ADT3_PIG LS1 66 <0.01 Glutamate carrier 1 F1RYY8_PIG LS1 49 <0.01
ATP synthase subunit α F1RPS8_PIG LS1 13 <0.01 Mitochondrial import
inner membrane
translocase subunin
F1SA66_PIG LS2 3 0.01
Ca2+-binding
mitochondrial carrier
protein Aralar2
I3L614_PIG LS1 17 0.01 Phosphatidate
cytidylyl-transferase
2
I3LAQ3_PIG LS1 5 <0.01
Elongation factor Tu F1RFI1_PIG LP1 22 <0.01 Pyruvate
carboxylase
F1RUV6_PIG LS1 7 0.01
Heat shock 60 kDa
protein 1
F1SMZ7_PIG LS2 22 <0.01 Heat shock 70kDa
protein 9 (Mortalin)
F1RGJ3_PIG LS1 2 <0.02
LETM1 and EF-hand
domain-containing
protein 1
F1S6V4_PIG LS2 60 <0.01 Trifunctional
enzyme α
ECHA_PIG LS1 7 <0.01
Endoplasmic reticulum
78 kDa glucose-
regulated protein
F1RS36_PIG LP2, LS2 3 0.03 Hypoxia up
regulated protein 1
F1SAI8_PIG LP2 4 0.04
Endoplasmin ENPL_PIG LS1 4 0.01 Reticulocalbin 2 F1SJ93_PIG All 15 <0.01
Plasma membrane
Excitatory amino
acidtransporter 1
F1SNA0_PIG LS1, LP2 4 0.03 Plasma membrane
Ca2+ ATPase 4
F1S6B3_PIG LS1 6 <0.01
Excitatory amino
acidtransporter 2
F1SHF9_PIG LS1 7 <0.01 Syntaxin-binding
protein 1
F1RS11_PIG LS1, LS2 23 0.05
Transmembrane
protein 33
F1S4G6_PIG LS1 399 <0.01
Cytoplasm
40S ribosomal protein S3 RS3_PIG LS2 7 <0.01 Dynein 1, light
intermediate chain 2
I3LQU0_PIG LS2 22 <0.01
40S ribosomal protein
S5-like isoform 2
F2Z5E6_PIG LP2 5 0.02 Glial ﬁbrillary acidic
protein*
F1RR02_PIG LS1 3 <0.01
60S ribosomal protein
L32
RL32_PIG LS1 19 <0.01 Glutamate
decarboxylase 2*
DCE2_PIG LS2 38 <0.01
52 kDa Rho protein F1RHN8_PIG LS2 2 0.03 Neuronal migration
protein doublecortin
I3L5C8_PIG LS1, LS2 53 <0.01
α-crystallin B chain CRYAB_PIG LP2 3 0.01 Rab GDP
dissociation inhibitor
α
I3L893_PIG LS1 8 0.01
Aminoacyl tRNA
synthase complex-
interacting
multifunctional protein 2
F1RFM7_PIG LP2 10 0.01 Ribosomal protein,
large, P2
F1RYZ0_PIG LS1 11 <0.01
ATP-citrate synthase F1S0N1_PIG LS2 58 0.02 S100 Ca2+ binding
protein A14
F1SFV3_PIG LS1 3 0.01
Ca2+-binding protein 1 F1RJI3_PIG LP2 10 0.01 Seryl-tRNA
synthetase
F1S5Z3_PIG LS2 261 <0.01
cAMP-dependent protein
kinase catalytic β
KAPCB_PIG LP2 5 0.01 T-complex protein 1
α
F1SB63_PIG LS2 373 <0.01
(Continued)
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Table 2. (Continued)
Protein UniProt/
swiss-Prot
Synapto-
somal
fraction
Fold
increase
p-
value
Protein UniProt/
swiss-Prot
Synapto-
somal
fraction
Fold
increase
p-value
Chaperonin containing
TCP1, subunit 2β
D0G0C8_PIG LS2 478 <0.01 T-complex protein 1
δ
F1SQN1_PIG LS1 11 0.01
Dynein 1 intermediate
chain 2
F1S087_PIG LS1 10 <0.01 T-complex protein 1
η
F1SLF6_PIG LS1 133 0.03
FMR1-interacting protein
2
F1RQE9_PIG LP2 3 0.02 T-complex protein 1
γ
F1RP17_PIG LS1, LS2 204 <0.01
Dihydropyrimidinase 2 I3LJE2_PIG LS1, LS2 23 <0.01 14–3–3 protein ζ/δ F2Z558_PIG LP1 2 0.04
Dynein heavy
polypeptide
F1S9Y5_PIG LS2, LP2 802 <0.01 14–3–3 protein γ F2Z4Z1_PIG LP1 9 0.03
Nucleus
A-kinase anchor protein
5
F1SA75_PIG LS1 9 0.01 Signal recognition
particle 54 kDa
protein
F2Z5M9_PIG LS2 18 <0.01
Vesicle
Amphiphysin I3L8X6_PIG LP2 5 0.03 Synaptic vesicle
glycoprotein 2A
F1SDF9_PIG LS1 9 <0.01
Nipsnap homolog 1 F1RFF5_PIG LP1 3 0.03 Tripeptidyl-
peptidase 1
I3L812_PIG LS2 45 <0.01
Sorting nexin 6 F1SHH3_PIG LS2 181 <0.01 Vacuolar protein
sorting-associated
protein 53
F1RHI3_PIG LP2 31 <0.01
Synapsin 1* B7TY10_PIG LS1, LS2,
LP2
9 0.01 V-type proton
ATPase subunit d 1
F2Z5H6_PIG LP2 2 0.03
Cytoskeleton
α-centractin F2Z5G5_PIG LS2 20 0.02 Spectrin α chain F1RR78_PIG LS1 3 <0.01
α-internexin F1S847_PIG LS1 3 0.02 Tubulin α-4A chain F2Z5S8_PIG LS1 6 0.01
Dynamin-2 F1S593_PIG LS2 64 <0.01 Tubulin β-3 chain F1S6M7_PIG LS1, LS2 15 0.01
Microtubule-associated
protein 6
F1SUM1_PIG LS1, LS2 28 <0.01 Tubulin β-4 chain F2Z5K5_PIG LS1, LS2,
LP2
9 0.01
Neuroﬁlament heavy
polypeptide
F1RFH3_PIG LP1 4 0.02 Tubulin
polymerization-
promoting protein
I3LB30_PIG LP1 3 0.04
Sirtuin 2 I3L8A1_PIG LS1 66 0.01
Secreted
Complement C4
precursor
F1RQW2_PIG LS1 2 0.01 C-type natriuretic
peptide
F1S0P3_PIG LS1, LP2 7 0.05
Complement C5
precursor
F1SME1_PIG LS2 19 <0.01 Tenascin-R F1S706_PIG LS2 8 0.01
Co-immunoprecipitations of proteins from detergent extracts of the synaptosomal fractions from porcine brain using recombinant αSN monomer, αSN
oligomer, or buffer as bait, were conducted, and the interacting proteins were identiﬁed by LC-LTQ orbitrap MS/MS. The identiﬁed proteins are speciﬁed
by name, Uniprot/swiss-Prot entry, and the synaptosomal fraction in which they were identiﬁed. Quantitative analyses were based on Peak Area Intensity
of peptides occurring in at least two of three individual immunoprecipitations. The average fold increase is calculated as the ratio between the peak areas
for monomer and oligomers for oligomer preferential binding proteins. The criteria of  2 fold increase compared to monomer had to be fulﬁlled in order to
be considered a preferential αSN oligomer binding protein. In order for a protein to be considered as either monomer or oligomer binding Student’s t-test
was applied to the logarithmic transformed peak areas and signiﬁcance < 0.05 was accepted.
* indicates the oligomer preferential proteins that were validated by western blotting in Fig. 3.
doi:10.1371/journal.pone.0116473.t002
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Table 3. Non-conformation speciﬁc αSN interacting proteins.
Protein UniProt/
swiss-Prot
Synaptosomal Protein UniProt/ swiss-
Prot
Synaptosomal
Mitochondrial
2-oxoglutarate dehydrogenase F1SSH8_PIG LP2 Mitochondrial carrier homolog 2 F1SIE0_PIG LP1
39S ribosomal protein L12 I3LSY1_PIG LP2 Mitochondrial import inner
membrane translocase subunit
F1RK50_PIG LP1
Adenine nucleotide translocator 2 F2Z565_PIG LS1, LP1 NADH dehydrogenase
[ubiquinone] 1 β subcomplex
subunit 10-like
I3LDC3_PIG LP1
ATP synthase subunit beta F1SLA0_PIG LP2 NADH dehydrogenase
[ubiquinone] ﬂavoprotein 1
F1RVN1_PIG LP2
Cytochrome b-c1 complex subunit 8-like
isoform 2
F1RI18_PIG LP2 NADP-dependent malic enzyme F1STS4_PIG LP1
Cytochrome c oxidase subunit 1 COX1_PIG LP2 Pentatricopeptide repeat domain
3
F1SVC4_PIG LP2
Chymodenin F1RLH7_PIG LP2 Prohibitin 2 I3LQN4_PIG LP1, LP2
Dihydrolipoyllysine-residue acetyltransferase
component of pyruvate
F1SMB2_PIG LP1, LP2 Pyruvate dehydrogenase:
subunit beta
F1SGH5_PIG LP2
Dihydrolipoyllysine-residue
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex
ODO2_PIG LP1, LP2 Short-chain speciﬁc acyl-CoA
dehydrogenase
F1RJH2_PIG LP1
Glutamate dehydrogenase 1 DHE3_PIG LP1 Thioredoxin-dependent peroxide
reductase
F1S418_PIG LS1
Hexokinase 1 F1SUF2_PIG LP2 Translocase of outer
mitochondrial membrane
F2Z4X6_PIG LP1
Long-chain 3-ketoacyl-CoA thiolase F1SDN2_PIG LP1 Voltage-dependent anion-
selective channel 1
VDAC1_PIG LP1, LP2
Endoplasmic reticulum
B-cell receptor-associated protein 31 F1S2A8_PIG LP2 Phospholipase D3 I3L5D6_PIG LP2
Ca2+/calmodulin-dependent protein kinase II
γ-B
Q7JFN4_PIG LP2 Protein disulﬁde-isomerase A6 E1CAJ6_PIG LP2
NADH dehydrogenase (ubiquinone) Fe-S
protein 5, 15 kDa (NADH-coenzyme Q
reductase)
F1SV23_PIG LP1, LP2 Stromal interaction molecule 1
precursor
F1SUZ4_PIG LP2
Plasma membrane
Adaptor-related protein complex 2, mu 1
subunit
I3LL07_PIG LP2 Immunoglobulin superfamily
member 8
F1RJW5_PIG LP2
AP-2 complex subunit β I3L6Y6_PIG LP2 Neural cell adhesion molecule 1 F1SM72_PIG LP1, LP2
BPI fold-containing family B member 1 I3LAK0_PIG LP2 Neurotrimin F1S6D0_PIG LP2
Brain acid soluble protein 1 isoform 1 F1SRL9_PIG LP1 Oligodendrocyte-myelin
glycoprotein
F1RJ55_PIG LP2
Ca2+/calmodulin-dependent protein kinase II
α
F1RL74_PIG LP2 Paralemmin-1 PALM_PIG LP2
Ca2+ modulating ligand F1RHC6_PIG LP2 Plasma membrane Ca2+ ATPase
2
I3LIE6_PIG LP2
Cell adhesion molecule 2 F1SK66_PIG LP2 Prohibitin F2Z543_PIG LP2
Cell cycle exit and neuronal differentiation
protein 1
CEND_PIG LP1 Protein RER1 I3LJC8_PIG LP2
Cytolytic trigger molecule G7 FCGR3_PIG LP1 Protein transport protein Sec61
subunit α2
F2Z5D0_PIG LP2
EH domain-containing protein 3 F1RQR4_PIG LP2 Thy-1 membrane glycoprotein
precursor
B9ZSM8_PIG LP2
Cytoplasm
(Continued)
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used to extract the four subfractions, synaptosomal membranes (LP1), soluble synaptosomal
lysate (LS1), and its subfractions synaptic vesicles (LP2) and synaptosomal cytosol (LS2)
(S1 Fig.). The sub-fractionation was conducted to reduce the complexity of the samples in
order to favor the downstreamMS based identification of proteins co-purifying with aSN or
Table 3. (Continued)
Protein UniProt/
swiss-Prot
Synaptosomal Protein UniProt/ swiss-
Prot
Synaptosomal
40S ribosomal protein S3a F2Z5C7_PIG LP2 Elongation factor 1-α Q0PY11_PIG LP2
60S ribosomal protein L6 RL6_PIG LP2 Elongation factor 1-β F1SHD6_PIG LP2
60S ribosomal protein L12 Q6QAS5_PIG LP2 Glutathione transferase ζ 1 F1S2N0_PIG LP1
60S ribosomal protein L22 RL22_PIG LP2 Heterogeneous nuclear
ribonucleoprotein K
I3LQS0_PIG LP2
60S acidic ribosomal protein P1 F1SIT7_PIG LP2 Proteasome subunit α type-2 I3LAB6_PIG LP2
ABI gene family member 3 isoform 2 I3LB01_PIG LP2 protein-arginine deiminase type-
2
I3LNE4_PIG LP2
AP-1 complex subunit sigma-1A Q06AS6_PIG LP2 Ribosomal phosphoprotein large
PO subunit
RLA0_PIG LP2
cAMP-dependent protein kinase type II-α
regulatory subunit
KAP2_PIG LP1 Protein kinase C ε type F1S5K7_PIG LP2
Creatine kinase I3LPB5_PIG LP1, LP2 S100 Ca2+ binding protein A16 F2Z5M4_PIG LP2
Cytoplasmic dynein 1 heavy chain 1 F1S9Y5_PIG LS2, LP2
Nucleus
Barrier-to-autointegration factor-like isoform
1
F1RU33_PIG LP1 Nucleosome assembly protein 1 F1SGD7_PIG LP2
Dynein light chain Tctex-type 3 I3LUI9_PIG LP2 WD repeat-containing protein 61 F1RKU4_PIG LP2
Homeobox prox 1 F1SFF4_PIG LP2
Vesicle
Membrane-associated progesterone
receptor component 1
PGRC1_PIG LP2 Syntaxin-1A F1RJM9_PIG LP2
Synaptic vesicle glycoprotein 2B F1SCI2_PIG LP2 Vacuolar protein sorting-
associated protein 45
F1SDG5_PIG LP2
Synaptotagmin-1 F1RYK1_PIG LP2 V-type proton ATPase subunit D F1SA40_PIG LP2
Vesicle-associated membrane
protein-associated protein B
VAPB_PIG LP2
Cytoskeleton
Actin related protein 2/3 complex, subunit 4 F1SQE6_PIG LP2 Dynamin-1 F1RRW8_PIG LP2
Actin-related protein 2/3 complex subunit 5 B5APV0_PIG LP2 Erythrocyte membrane protein
band 4.1
F1SM86_PIG LP2
Actin-related protein 3 F2Z5D2_PIG LP2 Microtubule-associated protein
1B
F1SK12_PIG LP1
Adenylyl cyclase-associated protein 1 I3LVT1_PIG LP2 Microtubule-associated protein 2
isoform 2
F1SSS6_PIG LS1, LP1
Cytoskeleton-associated protein 4 F1SPP8_PIG LP2 Septin 2 F1SIP0_PIG LS1
Secreted
Granulin F1RQZ0_PIG LP1, LS2
Co-immunoprecipitations of proteins from detergent extracts of the synaptosomal fractions from porcine brain using recombinant αSN monomer, αSN
oligomer, or buffer as bait, were conducted, and the interacting proteins were identiﬁed by LC-LTQ orbitrap MS/MS. The identiﬁed proteins are speciﬁed
by name, Uniprot/swiss-Prot entry, primary accession number, and the synaptosomal fraction in which they were identiﬁed. Quantitative analyses were
based on Peak Area Intensity on peptides occurring in at least two of three individual immunoprecipitations. The presented as αSN binding proteins
without any apparent conformational preferences are those where the ratio between peak areas for monomer and oligomers were < 2.
doi:10.1371/journal.pone.0116473.t003
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buffer control. The composition of the sub-fractions was analyzed by immunoblotting for pro-
teins known to be present in specific compartment. Synaptophysin, a marker for synaptic vesi-
cles, was enriched in LP2, but could also be detected in LS1 and LP1 (Fig. 1C). The content of
endoplasmic reticulum, was analyzed by the presence of 78 kDa glucose-regulated protein
(GRP78), and GRP78 was also enriched in LP2, and detectable in LS1, LP1, and LS2. The mito-
chondrial content was visualized by voltage-dependent anionic channel (VDAC) and found ex-
clusively in the LP1 fraction. Lamp2a, a marker for lysosomes, was enriched in LP2.
Furthermore, all the synaptosomal fractions contained a-tubulin.
First, we analyzed whether the oligomers and monomers were stable during the procedure
of co-IP by comparing their gel filtration behavior before and after incubation for 24 h at 4oC
in the detergent containing synaptosomal cytosol (2mg/ml recombinant monomer or oligomer
aSN in 1 mg/ml extract) as determined by anti-aSN immunoblotting of fractions correspond-
ing to O, and M (Fig. 1D). A fraction (I) eluting at 25 min, which is expected to contain low
amounts of exogenous aSN (Fig. 1A), was also analyzed in order to investigate a dissociation of
the oligomer into smaller species. The endogenous aSN level in the LS2 fraction was low, com-
pared to samples supplemented 2mg recombinant monomer or oligomer aSN, but can be de-
tected in the lysate sample without recombinant aSN primarily eluting as monomer (Fig. 1D).
The exogenous monomer eluted in the M fraction after incubation for 24 h with small amounts
of high molecular weight material present in fraction I. The oligomers also retained their elu-
tion in the high molecular weight fraction O, but with some dissociation into complexes eluting
in fraction I and with little detectable material in the fraction M, likely corresponding to endog-
enous porcine aSN. This shows that the purified oligomers and monomers largely retain their
molecular sizes during the incubation in detergent extract of brain lysates for 24 h at 4°C.
For proteomic analysis the brain extracts were incubated with recombinant human aSN in
its monomeric, and oligomeric state, or buffer-control followed by pull-down using the poly-
clonal aSN antibody ASY-1 coupled to sepharose beads. Co-IP proteins were identified by
tryptic peptide mapping by LC-MS/MS. Three identical experiments were conducted using the
four different synaptosomal preparations and each with monomeric, oligomeric aSN, or buffer
control as bait. The 36 individual co-IPs were analyzed by LC-LTQ orbitrap tandem mass spec-
trometry, which returned 11087 identifying peptides corresponding to 2049 proteins by search-
ing of a Sus scrofa database. The criterion to be fulfilled for proteins to be considered as
potential binding partners was identification in at least two of the three biological samples. To
compare if binding of a protein is preferential to aSN monomer or aSN oligomer, semi-
quantitative data was obtained as the peak area. The peak area of individual peptides varied
considerably between runs as exemplified by the peak area from ELEAVCQDVLSLLDNYLIK
peptide of 14–3–3 protein gamma that ranged from 397,866 to 1,415,206 in buffer controls,
from 509,836 to 724,293 in monomer samples and from 1,439,298 to 9,995,353 in oligomer
samples. In order to normalize the individual runs, a logarithmic transformation of the MS
peak area output was conducted before comparing the runs. This resulted for the
ELEAVCQDVLSLLDNYLIK peptide in control values from 5.6 to 6.15, monomer values from
5.71 to 5.86 and oligomer values from 6.16 to 7.0 thus demonstrating a significant difference
(p-value 0.03) between oligomer and monomer or buffer control when analyzed by student’s
t-test. A graphical illustration of the sample preparation, analysis and semi-quantitative analy-
sis and the criteria used can be found in S2 Fig.
A total of 178 proteins fulfilled the criteria of being aSN-binding proteins that are present
significantly higher in aSN fractions than in buffer controls. 87% of the aSN-binding proteins
occurred uniquely among one of the fractions. Tubulin beta-4 and synapsin 1 were present in
three fractions and only reticulocalbin 2 was present in all four fractions.
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The aSN binding proteins were filtered for their preferential occurrence in oligomer or
monomer samples based on the calculated average fold increase between the samples or those
being evenly distributed in these fractions. This resulted in lists of preferential monomer-
binding proteins (MP; Table 1), preferential oligomer-binding proteins (OP, Table 2) and
those not displaying preference between the aSN forms (NPB; Table 3). The tables also display
the predicted subcellular localization of the proteins based on Uniprot KB database.
Ten preferential monomer-binding proteins (Table 1) were identified and their predicted
subcellular localizations are dominated by mitochondria and cytosol (Fig. 2A). It should be
kept in mind that the detergent extraction removes all membranes and thus binding of e.g.
intra-mitochondrial proteins must be interpreted with caution.
The preferential oligomer-binding proteins (Table 2) comprised a large group of 76 that dis-
played a complex subcellular distribution although it was dominated by cytosolic and cytoskel-
etal proteins that may be immediately accessible to cytosolic aSN albeit a large group of
mitochondrial proteins were also present (Fig. 2B). It was reassuring to identify the protein
p25a/tubulin polymerization promoting protein in this group because it previously has been
identified as a preferential binder to aggregated aSN species [48].
The non-preferential group was the largest with 92 proteins (Table 3). Its subcellular distri-
bution was complex and slightly more evenly distributed between the categories than the pref-
erential oligomer-binding protein (Fig. 2C).
The increased binding of proteins to oligomers and monomers are displayed by the fold-
increase of binding to the corresponding aSN form (oligomer vs. monomer) based on the aver-
age of all their identified peptides (Tables 1 and 2). These values varied greatly from 2 to 802
and thus call for caution when interpreting the increase for proteins that are based on few pep-
tides. To corroborate their qualitative nature, we performed additional Co-IP experiments fol-
lowed by immunoblotting for selected proteins. Proteins for validation were selected based on
availability of well-characterized antibodies raised against human epitopes with at least 95%
identity to the porcine protein. As representatives for the preferential monomer-binding pro-
teins, Myelin proteolipid protein (mPLP) and Abl interactor 1 (Abl1) were chosen (Fig. 3A, B)
and for preferential oligomer-binding proteins, Glial fibrillary acidic protein (GFAP), Glutamate
decarboxylase 2 (GAD2), and Synapsin 1 (Syn1) were chosen (Fig. 3C, D). The data confirm
the aSN conformation preference identified by the MS-based technique. The quantitative analy-
ses of three individual pull-down experiments were conducted and resulted in approximately
4–6 times increased binding to oligomers vs. monomers for the oligomer preferential proteins.
The results for the monomer binding proteins also clearly demonstrated the preference for
monomers although the absolute value for the monomer preference of Abl 1 is unclear
because the oligomer binding was as low as the buffer control thus making estimation of ratios
pointless.
aSN has been demonstrated as a chaperone for Vesicle-associated membrane protein 2
(VAMP-2), also named synaptobrevin-2, in nerve terminals [7] so it was a surprise that we did
not detect VAMP-2 in our proteomic screen. However, inspection of the potential tryptic pep-
tides generated from VAMP-2 demonstrates that only 2 recognizable peptides can be formed.
Hence, such peptides may have been missed in the MS-based peptide search. Fig. 3E demon-
strates a co-IP analysis of the VAMP-2 binding to monomer and oligomer aSN. This clearly
demonstrates that oligomerization aSN enhances the interaction. In order to ensure that the
interactions were not artifacts due to species differences between human aSN and porcine
brain synaptosomal preparations, we performed validative Co-IPs using human brain synapto-
somal preparations, and were able to confirm the finding from porcine brain synaptosomal ex-
tracts (Fig. 3G-I).
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Figure 2. Subcellular localization of the αSN interacting proteins. A total of 178 proteins were identified
as αSN interacting proteins and they were grouped in proteins preferentially binding monomer αSN
(MP, N = 10, Table 1), oligomers (OP, N = 76, Table 2) and proteins not displaying any preferences
(NPB, N = 92, Table 3). They were grouped based on their subcellular localization as described by their
principal localization in the Uniprot database to demonstrate the aggregation state of αSN have potential for
significantly changing its cellular targets.
doi:10.1371/journal.pone.0116473.g002
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Figure 3. Validation of monomer and oligomer preference of αSN interacting proteins. Proteins pulled down by monomer αSN (M), oligomer αSN (O),
and buffer control (B) from porcine (A-F) and human (G-I) brain extracts were analyzed by immunoblotting using antibodies against antigens selected among
the monomer and oligomer binding proteins. Monomer binding antigens were myelin proteolipid protein (mPLP) and Abl interactor 1 (Abl1) and oligomer
binding proteins were glial fibrillary acidic protein (GFAP), glutamate decarboxylase 2 (GAD2), and synapsin 1 (Syn1). VAMP-2 was tested because it has
been reported to bind αSN, although it was not detected in our proteomic analysis. One representative of three experiments is presented for porcine αSN
binding proteins (A, C, E), and the quantification of the three experiments is presented in panels B, D, F. The quantification of bands was performed after
subtracting the non-specific signal in the buffer control from the specific bands in monomer and oligomer samples. Bars represent mean ratio between
monomer and oligomer S.D. of the three replicates. The values for binding to monomer and oligomer were compared by Student’s t-test and the resulting
p-values are listed above the bars. * Indicates that the band intensity from oligomer did not differ significantly from background making quantifications
impracticable. In order to ensure that the interaction were not due to species differences between human and porcine proteins we conducted validations in
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Discussion
The functionality of aSN in neurons is related to its state of aggregation. Native monomeric
species are hypothesized to conduct physiological roles in nerve terminals, where aSN is pres-
ent at high concentrations. In brain tissue affected by PD and DLB, aSN accumulates as soluble
oligomeric or protofibrillar species in terminals, axons and the somatodendritic compartment
and filamentous in Lewy inclusions and Lewy neurites. Moreover, aSN is also present in astro-
cytes in PD [52] and oligodendrocytes in MSA [53]. Hence, at least three factors have to be
considered for possible molecular pathogenic pathways initiated by aSN in disease (Fig. 4).
First, a gain of function by novel structures on aggregated oligomeric species. Second, novel
functions of aSN species, being monomeric and oligomeric, concentrated at abnormal sites like
axons and the cell body or in astrocytes and oligodendrocytes, where they will encounter new
interaction partners. Third, potential loss of function by the native monomer population if re-
duced due to aggregation or abnormal sorting.
We conducted a proteomic screen in sub-fractions from porcine synaptosomes to identify
potential interacting networks for aSN that could be affected in a-synucleinopathies. The
semi-quantitative proteomic screen was conducted using exogenous human aSN as bait in its
monomeric and pathological oligomeric state. Many types of in vitro formed aSN oligomers
have been reported, some forming spontaneously [41], some being stabilized by organic sol-
vents [54], and chemical modifications like dopamine [50] and some being off- versus on-
pathway in the aggregation process [55]. We choose to use the protocol for spontaneously
formed oligomers, which we have characterized extensively by surface hydrogen/deuterium
exchange combined with mass spectrometry and FILA-1 binding [36, 41, 51]. These oligomers
share surface epitopes for the conformational specific antibody FILA-1 with aSN oligomers
present in pathological human and mouse brain tissue [21–23]. It was imperative for the exper-
iment that the monomer and oligomer aSN retained their gross molecular structure during the
24h period of the incubations in order to perform a pull-down analysis of ligands for the two
conformations. This is especially critical because the non-modified oligomers we use display
some dissociation into monomers [51]. Comfortingly, we could demonstrate that the majority
of the exogenously added monomer and oligomer retained their sizes as determined by gel fil-
tration of the detergent brain extracts after the 24 h incubation. The elution of monomeric
input aSN as monomers after the incubation with brain extracts indicates most remains un-
bound or so loosely associated to targets that the complex dissociates during the gel filtration.
The large and heterogeneous size of oligomers based on their gel filtration profile does not
allow judgment of whether they have bound ligands or not by the subsequent gel filtration
analysis.
Using the above pull-down protocol 178 proteins were enriched in the aSN containing sam-
ples compared to the buffer control according to our specified criteria. These proteins were
selected from a total of 11087 MS spectra corresponding to 2049 proteins identified by search-
ing a Sus scrofa database containing all canonical sequences plus all manually reviewed isoform
sequences retrieved from UniProt (July, 2012). This number of spectra is comparable to the
number of spectra identified in a previous proteomic screen in mouse brain synaptosomes for
ligands of the C-terminal 40 residues of aSN [35]. We identified only 41 significantly enriched
proteins in the soluble synaptosomal lysate compared to 121 in its two resulting subfractions,
synaptic vesicles and synaptosomal lysate. This demonstrates the power of reducing the
human brain extracts. One representative of two experiments is presented for each validated protein. The validation for both porcine and human of mPLP,
Abl1, Syn1 and VAMP-2 was conducted in the LP2 fraction enriched in synaptic vesicle and the validation to GFAP and GAD2 in the LS1 fraction of
synaptosomal lysate.
doi:10.1371/journal.pone.0116473.g003
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complexity in targeted proteomic searches but also highlights a limitation in deciphering com-
plex interacting networks spanning cytosolic constituents and organelles. Of the 2049 identi-
fied proteins, 178 proteins had significant increased binding to aSN compared to background.
The 178 proteins could be grouped in three categories using> 2 fold-increase as indicative of
preferential binding. Preferential monomer binding proteins (MPB) are at risk of loosing their
function when aggregation occurs. Preferential oligomer binding protein (OPB) may initiate
novel conformation-dependent interactions and No-preference binding (NPB) are proteins
that can form novel interactions if the cellular/subcellular context of aSN is changed. To vali-
date the preferential binding to monomer, oligomer and buffer control by immunoblotting, we
selected mPLP and Abl1 among the 10 MPB, and GFAP, GAD2 and Syn1 among the 76 OPB
and obtained for all selected a positive validation of their predicted target preference. Three
amino acids differs between human and porcine aSN, so in order to ensure that the identified
interactions were not artifacts due to these differences, the interactions were all positively vali-
dated using human synaptosomal preparations. This supports the concept of groups of cellular
proteins preferentially binding either monomeric or oligomeric aSN and thus representing in-
teraction networks at risk of being offset in a-synucleinopathies. The larger number of identi-
fied interaction partners of OBP compare to MBP could be due to the unfolded nature of
monomer aSN compared to oligomer that display distinct structural feature as demonstrated
by antigen presentation [21] and deuterium exchange mass spectrometric analysis [51].
Figure 4. Possible molecular pathways initiated by αSN in disease. Under normal conditions αSN is predominantly located in nerve terminals (blue).
During disease αSN undergo aggregation and this lead to novel conformation-dependent interactions (red), which represents a gain of function. In addition,
αSN species (monomeric and oligomeric) are concentrated at abnormal sites, like axons and the cell body, or in astrocytes and oligodendrocytes, which give
rise to novel interactions because new partners are introduced (green). Finally, an abnormal sorting and aggregation leads to a loss of, or reduced normal
αSN concentration in nerve terminals where critical monomer specific interactions will be compromised thus representing a loss of function.
doi:10.1371/journal.pone.0116473.g004
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aSN is considered a predominantly cytosolic protein and cytosolic proteins also represent
the largest group with 51 of 178 aSN binding proteins. However, it is evident that aSN species
holds potential for targeting proteins in organelles like mitochondria, endoplasmic reticulum,
vesicles, plasma membrane and cytoskeleton. As cautionary note, one must be aware that the
use of detergents dissolve natural membrane barriers and may give rise to false positive interac-
tions. With that mentioned, mitochondria have previously been reported to interact with and
take up aSN [56, 57] and cellular aSN expression increases mitochondrial calcium uptake [58]
and reduces mitochondrial membrane potential [59]. Our data support that aSN can modulate
mitochondrial functionality as we confirm binding to the previously found mitochondrial
chaperone mortalin [34] and identify novel targets e.g. in the outer mitochondrial membrane
like voltage-dependent anion-selective channel protein 1 and translocase of outer mitochondri-
al membrane but also components involved in ATP production like ATP synthase subunits
alpha and beta. Interestingly, ATP synthase subunit alpha is increased in aSN expressing
SH-SY5Y cells [60].
Autophagy has attracted significant interest in PD research because of its ability to
degrade intracellular proteins in general and misfolded proteins in particular [61] and because
mutations in lysosomal glycocerebrosidase, causing Gaucher’s disease, increase the risk of de-
veloping PD [62]. Moreover, dysfunctional autophagic flux results in increased cellular excre-
tion of aSN species, which have been sampled from the cytosol by quality control autophagy
[63]. Such species may hold increased potential for spreading misfolded aSN to other cells
compared to the normal constitutively excreted aSN. Tightly regulated vesicle sorting and
acidification of vesicular content is critical for the autophagic flux and proper enzymatic
degradation of its cargo. We find aSN hold potential for disturbing these processes because
the all three aSN binding fractions contain subunits associated with acidifying proton
pumps (V-type proton ATPase subunit D, D1 and F), along with vacuolar sorting proteins
(vesicle-associated membrane protein-associated B; vacuolar protein sorting-associated
protein 53).
aSN aggregates have been demonstrated in synaptic terminals of brain tissue affected by
Lewy body dementia [25]. In the terminals oligomers may inhibit normal synaptic vesicle func-
tion because aSN oligomers display increased binding of synaptic vesicle proteins amphiphy-
sin, synapsin 1, synaptic vesicle glycoprotein 2a and VAMP-2 (also known as synaptobrevin 2).
aSN has been demonstrated to function as a critical chaperone for VAMP-2 function [7]
and this function is hypothesized to rely on a tethering mediated by vesicle binding to the
N-terminus and VAMP-2 binding to the C-terminus of aSN [64]. Oligomerization of aSN will
enhance VAMP-2 binding and likely inhibit the ordered tethering mediated by native aSN.
We did not identify VAMP-2 by our proteomic investigation, but could demonstrate its prefer-
ential binding to oligomers by co-IP. This highlights the limitations of proteomic studies where
negative results have to be interpreted with care.
Calcium dysregulation is potentially involved in sporadic PD because treatment with calci-
um antagonists in epidemiological studies has demonstrated a protective effect [65]. We find
that the type 4 plasma membrane Ca2+ ATPase displays increased binding of oligomeric aSN,
whereas binding to type 2 plasma membrane Ca2+ ATPase displays no conformational prefer-
ence. Additionally, we have in another pull-down study demonstrated increased binding of
aSN oligomers to ER-associated Ca2+ ATPase and this interaction functionally activates the
pump (Betzer, Jensen, Manuscript in preparation). Hence, aggregation and redistribution of
aSN from its normal presynaptic localization to larger neuronal compartments hold the poten-
tial of dysregulating these important Ca2+ pumps, which are critical for restoring normal cyto-
solic calcium levels after locally increased Ca2+ transients involved in signaling. Likewise,
dysregulation of excitatory amino acid transporter 1 by aSN oligomeric may affect the removal
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of glutamate from the synaptic cleft [66] and thus cause hyperactive glutamate signaling and
potentially excitotoxicity.
Dysregulation of protein translation has recently been associated to PD by the demonstra-
tion of mutations in the translation initiation factor EIF4G1 in familial PD [67] and the identi-
fication of specific R1205H variant as a PD risk factor [68]. We did not identify EIF4G1 or its
directly interacting partners, but demonstrate several proteins associated to the subsequent
steps in protein translation, elongation factors 1 alpha and beta, 40S ribosomal proteins S3,
S3a, S5-like protein isoform 2, 60S proteins L6, L12, L22, L32 and acidic ribosomal protein
3-like isoform 2. Among these interactions are both aggregate and non-aggregated dependent
interactions. Association of dysregulated protein synthesis in PD was thus initially highlighted
by the EIF4G1 mutations [67], but our findings suggest that PD causing defects in protein syn-
thesis can be triggered by dislocalized or misfolded aSN at other levels in this biosynthetic
pathway.
Potential targets in signaling cascades were also identified. The cAMP and Protein kinase
A (PKA) signaling system may be affected at more levels by interactions with catalytic subunit
beta, regulatory subunit type 2, as well as scaffolding A-kinase anchor protein 5. Such interac-
tions may be involved in the aSN dependent attenuation of cAMP dependent TH gene expres-
sion in cells [69]. Additionally, we identified Protein kinase C epsilon, calcium/calmodulin-
dependent protein kinase type 2, alpha subunit and creatine kinase thus linking aSN sensitive
targets to phospholipase C and its substrate diacylglycerol, calcium regulation and
bioenergetics.
Unfolded protein stress in an aSN transgenic mouse, was associated to accumulation of mis-
folded aSN species in the endoplasmic reticulum of brain tissue and such accumulation was
also demonstrated in humans brains affected by a-synucleinopathies [22]. Our demonstration
of protein disulfide-isomerase A6 binding to aSN could provide a mechanistic link between ac-
cumulated aSN aggregates and interference with protein disulfide bridge formation, folding
and ER stress.
The strong preference for sirtuin 2 binding to oligomeric aSN may indicate direct protein-
protein interactions as involved in the role of protein deacetylase sirtuin 2 in nigrostriatal dam-
age in toxic and aSN transgenic PD models [70, 71].
Conclusion
We identify a range of aSN interacting brain proteins among which several displays monomer
and aggregate specific preferences. The identified ligands validate proteins previously reported
to interact with aSN (including actin [33], tubulins [72, 73], p25a [48], and mortalin[34]), but
also highlights novel proteins from pathways already hypothesized to be involved in the molec-
ular pathogenesis of a-synucleinopathies like calcium regulation, mitochondrial homeostasis,
protein translation, kinase signaling and vesicular and lysosomal function. Hence, the data
may both corroborate current hypotheses by expanding their involved targets and contribute
to the generation of novel hypotheses.
Supporting Information
S1 Fig. Fractionation process for generating the synaptosomal fractions for the interaction
analysis. Porcine and human brain tissue was homogenized and subjected to differential cen-
trifugation as described in Materials and Methods. Enclosed in the dashed box is the four syn-
aptosomal preparations; synaptosomal membranes (LP1), synaptic lysate (LS1), synaptic
vesicles (LP2), and synaptic cytosol (LS2), which were used in the co-immunoprecipitations
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and subsequent identifications of aSN binding proteins upon solubilized in 0.5% Triton X-100.
(TIF)
S2 Fig. Schematic illustration of the workflow and decision making used in the semi-quan-
titative mass spectrometric analysis. Brain tissue is prepared and fractioned resulting in four
synaptosomal fractions (LP1, LS1, LP2, and LS2) before being mixed with either aSN mono-
mer, oligomer, or buffer control yielding 12 samples. By conducting the investigation on three
biological replicates this gives a total of 36 samples. The 36 samples were processed by co-IP,
tryptic digestion, fractionation and analysis by LC-LTQ orbitrap tandem mass spectrometry.
Peptides identified in at least two of the 36 samples were analyzed by integrating the peak area
intensity (PAI) using Skyline to obtain semi-quantitative information. The semi-quantitative
data was logarithmic transformed to reduce variation between biological replicates. All the
quantitative data were manually inspected for peptides with higher buffer values compared to
monomer or oligomer values and these peptides were excluded. To determine conformation
preferences among identified ligand interactions a ratio was calculated between monomer sig-
nal and oligomer signal for each of the three biological replicates. The significance was tested
by Students t-test and significant average fold increase of 2 or more designates conformation
preferential binding.
(TIF)
S3 Fig. Presence of aSN binding proteins chosen for validation in synaptosomal fractions.
30mg of each of the fractions synaptosomal membranes LP1, synaptosomal lysate (LS1), synap-
tic vesicles (LP2) and synaptosomal cytosol (LS2) were immunoblottet, and analyzed for the
presence of myelin Proteolipid protein (mPLP), Abl interactor 1 (Abl1), Glial fibrillary acidic
protein (GFAP), Glutamic acid decarboxylase 2 (GAD2), Synapsin 1 (Syn1), and Vesicle asso-
ciated membrane protein 2 (VAMP2).
(TIF)
S1 Table. Semi-quantitative data frommass spectrometric analysis. semi-quantitative analy-
sis of protein binding to alpha-synuclein, subsectioned into three conditions, monomer bind-
ing proteins, oligomer binding proteins, and no difference in binding monomer and oligomer
including number of identified peptides, number of quantified peptides, and percent sequence
coverage.
(XLSX)
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